Myocardial perfusion imaging in cardiac sarcoidosis: A “sine qua non” for prognosis assessment?

Excerpt

Sarcoidosis is a heterogeneous, granulomatous disorder of unknown etiology with multiorgan involvement. Cardiac involvement may range from asymptomatic granuloma infiltration to clinically conduction disturbances, ventricular arrhythmias, progressive heart failure and sudden death and has important prognostic and therapeutic implications. Multimodality imaging plays an important role in the diagnosis of cardiac sarcoidosis but also in the assessment of treatment efficacy. To date gallium-67 scintigraphy, cardiac magnetic resonance imaging (cMRI), and ¹⁸F-Fluorodeoxyglucose positron emission tomography (FDG-PET) have been included as imaging diagnostic tests in guidelines and in expert consensus documents.1,2 FDG-PET and increasingly cMRI aside diagnostic purposes can also provide information for the risk assessment and management of the disease.3 …